Nov 15, 2019 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q2 FY '20 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.
Jason D'souza - Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy
Thank you, moderator. Welcome to Glenmark's Q2 Earnings Call.
Before we open the floor for question and answer, the review of the operations for the quarter ended September 30, 2019. For the second quarter of FY '20, Glenmark's consolidated revenue was at INR 28,150 million, recording an increase of 9.05%. For the first 6 months of the financial year, Glenmark's consolidated revenue was at INR 51,379 million, recording an increase of 8.2%.
India. Sales from the India formulation business for the second quarter was at INR 8,963 million, recording a growth of 15.16%. The India business continues to outperform the industry growth. As
Q2 2020 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot